Real-time enrollment status for this relapsed/refractory primary central nervous system lymphoma clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 1:02 PM UTC
| NCT Number | NCT07104032 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory Primary Central Nervous System Lymphoma |
| Phase | PHASE3 |
| Target Enrollment | 132 participants |
| Active Locations | 24 sites in the US |
| Sponsor | Ono Pharmaceutical Co., Ltd. |
| Last Updated on CT.gov | October 1, 2026 (1 week ago) |
As of October 12, 2026: Clinical trial NCT07104032 is currently recruiting participants. This phase3 study for relapsed/refractory primary central nervous system lymphoma is actively seeking new participants at 24 locations across the United States. The study is sponsored by Ono Pharmaceutical Co., Ltd.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07104032 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 24 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07104032 was last updated 1 week ago (October 1, 2026). HelloStudys verifies this status automatically.